{"name":"Geert D'Haens","slug":"geert-d-haens","ticker":"","exchange":"","domain":"","description":"Geert D'Haens is a biopharmaceutical company focused on the development and commercialization of innovative therapies in immunology. The company's lead product, Vedolizumab 300 mg, is currently marketed for the treatment of inflammatory bowel diseases.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPNGtxbGlqUzRBWnh1UE14MHRpZkQwM3dCY2VtNTkxeFk5d2hYdFRFb0RaNVBuYXJqLWJwbHRnSnU1SHpvclJndGY0Xy1wQkxJdjJoejRsN3RFTTg3UFRia1c4OHI1dVhVWHhkNzBaTW9UWFpaQzNSMnhMclhsUDZKNUlsTHRMWnlzZTlxOXJ6S2ZHcnhRcjNUN290MkxKeEpCOHNSWGZoc1RLb1p0?oc=5","date":"2025-10-06","type":"pipeline","source":"takeda.com","summary":"Aiming to stop Crohn's disease before it starts | Takeda Stories - takeda.com","headline":"Aiming to stop Crohn's disease before it starts | Takeda Stories","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9hU1kycF9scUc4VFAzc2xaaXpaUGhGN2hqOEFhb2ZnOC1ZbHlxZTZPSXVFLUx2ZWpKNXB5WFdzTVpPeEtUVl9hR3VqMDRONjFxNVd2WVpoV0hhVFVaYTNr?oc=5","date":"2024-07-17","type":"pipeline","source":"NEJM","summary":"Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease - NEJM","headline":"Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9rcC1MVHFSMnNHc3BERlZfZTZ2UVFwRkhUSS05SGZNRW4wYnF0akVRVnVfX1oxMUJvYTU0OWsxQnVCenpxZUVDY1lITklkblpDelQ4ZVRHMFdrTm5GbjMwSndzQjBIX3phRXlj?oc=5","date":"2023-05-04","type":"trial","source":"Wiley Online Library","summary":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial - Wiley Online Library","headline":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to W","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNaGc4YmN0aGRiYW1sYjNJV2haYWNDdHc3MGF2RWdYczBCS2JfMEpPOGU5dXpGeUh0czg5NFhnWlJPYkM0TGxoTTBGYk4xVUNXdVJqTldqam1JX3h6eXJRc0lMVkVJbHR3RF9XeVNYZjE2eloyUVoydDVaa0ZsdHdUWV9Nc1BQWWZsSTRPRl94ZlFDOE9YYkpNWFhPaEd0eXQtN00zdDgtS0VvVWlPLVpfM3FXRndXM0Rla2NhaG5HaDhGODE1V0xLUVRtZ0hBa3c?oc=5","date":"2018-06-07","type":"pipeline","source":"European Medical Journal","summary":"Anti-Tumour Necrosis Factor in Inflammatory Bowel Disease: Inventory and Outlook - European Medical Journal","headline":"Anti-Tumour Necrosis Factor in Inflammatory Bowel Disease: Inventory and Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNOFhOaTZ2alpJTi1fQjVJWGNvd3g0d09RdlJWU3FJMVBUU2VFdVRSWG1mOGoycVVfdTN2ZjdpVzdhckt4dVBYbGxsdmJzbzk5T3JUbVJtYnkyLS0xQXZsZXBkWnRJRndTQmx3SXdzcXVfYjJmQnhEQUZGbFdIUzZwWFgwWkFnaGV2clluYzFuR1VqODR6SHRaZXFYMGxQUnJCSXFQamV5M0RhMzNKeE9KaC1TYkpGU1A1S0JtR2tMeHBheVlFdEtEWmt1Y0dQZWJhNUZldDNNcnVsNm92YklqTXFqdHQ?oc=5","date":"2018-03-01","type":"pipeline","source":"European Medical Journal","summary":"Mission: Rapid Action and Lasting Remission: A Focus on Disease Progression in Ulcerative Colitis - European Medical Journal","headline":"Mission: Rapid Action and Lasting Remission: A Focus on Disease Progression in Ulcerative Colitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNakF5MmlTT0E5SVdwYUJGRDdXTEJVdGh6S3JtSjNULWY1SWlQWlgySlNzcDFqWFZXVUd3ckxZbXNHUTc2dEo2WGlGTi13ZW1HeTYxWC01WFpjNmFuZXNscXllaHMxMFNMWUpvNGotMk5haGVfRHNmTmlERzQ4SHc3dklnRDhPVVBTUVFnS1NYM2hNc3o5SWxhX2FvLVFndFo2elFQMUlMZGN1ZFVvUTlSQTV6aDQ?oc=5","date":"2017-12-14","type":"pipeline","source":"European Medical Journal","summary":"Keep Calm and Treat to Target in Inflammatory Bowel Disease - European Medical Journal","headline":"Keep Calm and Treat to Target in Inflammatory Bowel Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBoRE1raFVhTGdvYVlqbDJYNUxHaVdjSUstbmF4bzlxaVpkQXhqT21HRHhza1ZHOXpORXk5OWlENFBuTHU2YjZhNHlkdVZHUDNyX2dIMzNySDg5MTdWVjRVbQ?oc=5","date":"2016-05-05","type":"pipeline","source":"NEJM","summary":"Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis - NEJM","headline":"Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNbHVuVmZpenprQ0NLRm4yem5RVmtVZWZLQlg0c2JRc3hKbkJCSzVQa18tOExOWUpKcGxKV0ZRdGlGSGlLeWJvcV9lb2FKMmxtSENfdGw2cUtXcmJScHhxZnBUUFV6TTVkcDJYeXZGUmFKQU1HMFpjc0JobVY4MlVXc0dHd0NDNXFnWDFudnJfclVfV29qd0pLRTNlZ3ZOeV93UGFmdjhKQWk5Nk1OWmhiYXZn?oc=5","date":"2016-01-25","type":"pipeline","source":"European Medical Journal","summary":"An interview with Professor Geert D’Haens at the 23rd UEG Week - European Medical Journal","headline":"An interview with Professor Geert D’Haens at the 23rd UEG Week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBxbUR5Tm1mZTFFV29KQXo0YUgzNVdnNHh4S0o1TzlTTEZTLXpLSWVFam5zTExvT0JmX0dtUy1sZ1p1Nkk2TXB6U2JWcUVvM0czeVh3ZWZVdVRVU3lvQnF0Yg?oc=5","date":"2010-04-15","type":"pipeline","source":"NEJM","summary":"Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease - NEJM","headline":"Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}